Ipsen Manufacturing
Ipsen is a biotechnological group aiming to become a leader in specialty healthcare solutions for debilitating diseases. Its strategy is supported by three franchises, neurology, endocrinology and urology-oncology.
Ipsen has a growing portfolio in prostate cancer, bladder cancer or neuro-endocrine tumours and a presence in primary care.
The group has more than 4,500 employees spread across R&D and manufacturing sites located in China, France, Ireland, the UK and the US.
Financial Data
-
31st Dec 18 Source: CRO
- €143.5 million turnover
-
€121.8 million
profit - 141 employees
-
31st Dec 17 Source: CRO
- €122.2 million turnover
-
€104 million
profit - 125 employees
- 6 more years available »
Ranking
By Turnover
(€143.5 million)- 390th in Top Companies
- 41st in Health
- 41st in Pharma
- 59th in Manufacturing
By Employees
(141)- 653rd in Top Companies
- 78th in Health
- 59th in Pharma
- 99th in Manufacturing
- 141
- €143.5 million
Employees
- James Byrne General Manager
Latest News
- Jul 07 High Court refuses Denis O’Brien application for discovery of documents
- Jul 07 Spar-owner BWG explores potential for online shopping ‘pot of gold’
- Jul 07 SuperValu and Centra MD Martin Kelleher stepping down
- Jul 07 European shares fall on warning of deeper recession than expected
- Jul 07 Facebook must get better at dealing with hate speech, says Sheryl Sandberg